Dietary supplement
ENTitis®
for school-age
children
Lozenges for children over 3 years of age and adults
30 lozenges
Flavour:
What is ENTitis?
ENTitis® contains a unique strain of Streptococcus salivarius K12, which is the result of a surprising discovery by a world-renowned microbiology professor, who discovered it in an exceptionally resilient boy.
Unique formula:
ENTitis® is the only oral product in Poland that includes the Streptococcus salivarius K12 strain in the Bactoblis® formula, which is the result of over 30 years of research by scientists. The S. salivarius K12 strain contained in the Bactoblis® formula colonises the oral cavity and nasopharynx.
Scientific research:
The Streptococcus salivarius K12 strain (in the Bactoblis® formula) found in the ENTitis® preparation has undergone numerous scientific studies.
Who is ENTitis for?
ENTitis in tutti frutti-flavoured lozenges has been specially designed for older children, particularly for:
- children in group care environment (e.g. school),
- during the spring equinox,
- to support the body during the autumn-winter season.
The product can be used by children aged 3 and older.
A balanced diet and healthy lifestyle are important for maintaining health.
Ingredients
Filling agent: isomalt; Streptococcus salivarius K12 (milk); anti-caking agent: magnesium salts of fatty acids; flavouring, cholecalciferol (vitamin D).
| Content of vitamins and other active ingredients in the recommended daily dose – 1 lozenge: | |
| Streptococcus salivarius K12 | 1 × 109 CFU* (1 billion) |
| Vitamin D | 5 μg (200 IU 100% GDA**) |
*CFU – colony-forming unit
**GDA – % of Guideline Daily Amount (for adults)
Recommended daily dose
1 lozenge per day
min. 3 months
1 lozenge per day for a minimum of 3 months.
When used as directed (for a minimum of 3 months), ENTitis supports the immune system for several months after discontinuation of its use.****
Do not exceed the recommended daily dose.
Directions for use
The lozenge should be taken before bedtime after brushing the teeth, allowing the strain to effectively colonise the oral and nasopharyngeal cavities overnight. The tablet should be slowly sucked for about 5 minutes until it is completely dissolved. To ensure maximum contact of the active substance with the throat mucosa, the tablets should not be chewed or swallowed. Do not drink water immediately after administration.
Nearest pharmacy
Pharmacies near your location. See on the map where you can find our products.
Buy online
Find the best deal on ceneo.pl and order our products online now.
Choose your ENTitis®:
ENTitis®Baby
Sachets for infants over 6 months of age and children
DIETARY SUPPLEMENT
30 sachets with strawberry or banana flavour
ENTitis®
lozenges for children over 3 years of age and adults
DIETARY SUPPLEMENT
30 lozenges with strawberry flavour
ENTitis® biotyk
Lozenges for children over 3 years old and adults for use during antibiotic therapy.
DIETARY SUPPLEMENT
30 lozenges with tutti frutti flavor
*ENTitis is the only product in Poland containing the Streptococcus salivarius K12 strain in the Bactoblis® formula. Bactoblis® is a registered trademark of PharmExtracta S.p.A and is licensed on an exclusive basis by Bluestone Pharma GmbH. Bactoblis® is available as a slowly dissolving formula containing no less than 1 billion colony-forming units of the Streptococcus salivarius K12 strain.
** ENTitis contains the Streptococcus salivarius K12 strain and vitamin D, which contributes to the proper functioning of the immune system.
***List of scientific studies for the K12 strain in the Bactoblis® formula:
1.Di Pierro F. et al. Int J General Medicine, 2012:5, 991–997. 2. Di Pierro F. et al. Clinical Evaluation: Streptococcus salivarius K12 for Recurrent Pharyngitis Prevention in Adults, 2013, 1-5. 3. Di Pierro F. et al. Drug, Healthcare and Patient Safety, 2014:6, 15–20. 4. Di Pierro F. et al. Int J General Medicine, 2015:8, 303-308. 5. Gregori G. et al. Therapeutics and Clinical Risk Management, 2016:12, 87-92. 6. Di Pierro F. et al. Drug, Healthcare and Patient Safety, 2016:8, 77-81. 7. Di Pierro F. et al. Eur. Rev. Med. Pharm. Sci.,2016:20, 4601-4606. 8. Gun T. Paripex Indian J. Res., 2017, 633-634. 9. Kryuchko T.O., Tkachenko O.Ya., Ukrainian Med. Dent. Acad., Lantibiotics for Preventing Recurrent Upper Respiratory Tract Infections in Children, 2017, 27-32. 10. Di Pierro F. et al. Edizioni Minerva Med., 2018, 70(3):240-245. 11. Gavrilenko Yu.V., Prevention of Recurrent Pharyngeal Infections in Children with Antibiotics, 2018, 82-94. 12. Marushko T.V. et al. Streptococcus salivarius K12 in Preventing and Treating Chronic Tonsillitis in Children, 2018, 82-88. 13. Kruchko T.O., Tkachenko O. Ya. Clinical Use of Streptococcus salivarius K12 for Preventing Pharyngotonsillitis and Respiratory Infections in Children, 2018, 122-127. 14. Marini G. et al. Int J General Medicine, 2019:12, 213-217. 15. Havrylenko Yu.V. Clinical Use of Respiratory Probiotic Bactobolis in Children with Secretory Otitis Media, 2019, 90-93. 16. Ilchenko S.I. et al. Pediatrics. Eastern Europe, 2019, 559-565. 17. Bezshapochny S.B. et al. Optional Location Therapy for Chronic Tonsillopharyngitis Remission, Otorhinolaryngology 3(3), 2020, 38-42. 18. Sarlin S. et al.The Pediatr. Infect. Dis. J. 2020;XX:00-00, 1-9. 19. Karakov K. G. et al. Actual problems in dentistry, 2020, 18-21. 20. Kramarev S. O. et al. Actual Infectology, Application of S. salivarius K12 Probiotic in Acute Tonsillopharyngitis Treatment in Children. 2020, 6-11. 21. Ilchenko S.I. et al. Actual Infectology, Efficiency of Respiratory Probiotic S. salivarius K12 in Children with Recurrent Tonsillitis, 2020, 35-39. 22. Kryuchko T.O., Tkachenko O.Ya. Nutrafoods, 2021, 1:246-253. 23. Kryuchko T.O., Tkachenko O.Ya. Nutrafoods, 2021, 2:254-261. 24. Savlevich E.L. et al. Vestnik otorinolaringologii, Vol. 86, No. 6, 2021, 42-47. 25. Puhlik S.M. et al. Experience with Oral Probiotic S. salivarius K12 for Preventing Recurrent Pharyngotonsillar Episodes, 2021, 120-124. 26. Wang Q. et al. Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study, 2021. 27. Di Pierro F. et al. Minerva Medica 2021, 112(4):514-6. 28. Kryuchko T., Tkachenko O. et al. Pediatrics. Eastern Europe, 2021; 9(3), 482-491. 29. Guo H. et al. Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season, 2022. 30. Babina K. et al. A Pilot Random. Clinical Trial. Nutrients, 2022, 7;14(5):1124. 31. A.Y. Ovchinnikov et al. Possibilities of probiotic therapy in chronic inflammatory diseases of the oropharynx. Effective pharm. 2022; 18 (4): 24–28. 32. Zangrilli A. et al. Probiotics and Antimicrobial Proteins, 2022, 14:573–578. 33. Di Pierro F. et al. Microorganisms, Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study 2022; 10(10):1926. 34. La Torre F. et al. Preliminary data revealing efficacy of SSK12 in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry, 2023. 35. Bertuccioli A. et al. Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised doubleblind study, 2023.
**** Based on research by: Di Pierro F. et al. Expert Opin Biol Ther. 2013 Mar;13(3):339-43.
